The ongoing clinical trial of a promising Ebola vaccine has been suspended in Geneva following complaints of observed side-effects by some volunteers. Sixty people were injected with the vaccine to determine its clinical effectiveness against Ebola virus out of whom four complained about problems in their hands and feet.
“So far the side effects have only been detected in Geneva,” says Professor Laurent Kaiser, one of the directors of the vaccine trials. “Maybe because here the volunteers are closely monitored. We have lots of medical personnel and volunteer doctors. The symptoms have only been weak and didn’t last long. Maybe here they have been detected a little more accurately.”
Health authorities have discontinued running the trial but will surely resume with it next year when affected participants will have been thoroughly examined to analyze the causes of their complaints.
Several companies including GlaxoSmithKline, NewLink, and Johnson & Johnson among others are at the forefront of developing Ebola vaccines, and they are speeding up research efforts to make the drug available within the shortest period of time at the cheapest cost rates in the face of the epidemic ravaging parts of West Africa.
Over 6,000 people have been killed so far by the Ebola virus in Liberia, Guinea, and Sierra Leone and world governments are committing a lot of financial and personnel efforts to combat the disease to a standstill.